What outcomes was the LEADER trial powered to assess? Can you specifically discuss the secondary microvascular outcomes in the kidney?

What outcomes was the LEADER trial powered to assess? Can you specifically discuss the secondary microvascular outcomes in the kidney?

What outcomes was the LEADER trial powered to assess? Can you specifically discuss the secondary microvascular outcomes in the kidney?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Johannes F.E. Mann, MD

Johannes F.E. Mann, MD

Professor of Medicine
University of Erlangen-Nürnberg
Director, Dept. of Nephrology, Hypertension & Rheumatology
Munich General Hospitals
Munich, Germany